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BACKGROUND. Monogenic IFN–mediated autoinflammatory diseases present in infancy
with systemic inflammation, an IFN response gene signature, inflammatory organ damage,
and high mortality. We used the JAK inhibitor baricitinib, with IFN-blocking activity in vitro, to
ameliorate disease.
METHODS. Between October 2011 and February 2017, 10 patients with CANDLE (chronic
atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures), 4 patients
with SAVI (stimulator of IFN genes–associated [STING-associated] vasculopathy with onset
in infancy), and 4 patients with other interferonopathies were enrolled in an expanded
access program. The patients underwent dose escalation, and the benefit was assessed by
reductions in daily disease symptoms and corticosteroid requirement. Quality of life, organ
inflammation, changes in IFN-induced biomarkers, and safety were longitudinally assessed.
RESULTS. Eighteen patients were treated for a mean duration of 3.0 years (1.5–4.9 years).
The median daily symptom score decreased from 1.3 (interquartile range [IQR], 0.93–1.78)
to 0.25 (IQR, 0.1–0.63) (P < 0.0001). In 14 patients receiving corticosteroids at baseline,
daily prednisone doses decreased from 0.44 mg/kg/day (IQR, 0.31–1.09) to 0.11 mg/kg/day
(IQR, 0.02–0.24) (P < 0.01), and 5 of 10 patients with CANDLE achieved lasting clinical
remission. The patients’ quality of life and […]
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BACKGROUND. Monogenic IFN–mediated autoinflammatory diseases present in infancy with systemic inflammation, an IFN 
response gene signature, inflammatory organ damage, and high mortality. We used the JAK inhibitor baricitinib, with IFN-
blocking activity in vitro, to ameliorate disease.
METHODS. Between October 2011 and February 2017, 10 patients with CANDLE (chronic atypical neutrophilic dermatosis with 
lipodystrophy and elevated temperatures), 4 patients with SAVI (stimulator of IFN genes–associated [STING-associated] 
vasculopathy with onset in infancy), and 4 patients with other interferonopathies were enrolled in an expanded access 
program. The patients underwent dose escalation, and the benefit was assessed by reductions in daily disease symptoms 
and corticosteroid requirement. Quality of life, organ inflammation, changes in IFN-induced biomarkers, and safety were 
longitudinally assessed.
RESULTS. Eighteen patients were treated for a mean duration of 3.0 years (1.5–4.9 years). The median daily symptom 
score decreased from 1.3 (interquartile range [IQR], 0.93–1.78) to 0.25 (IQR, 0.1–0.63) (P < 0.0001). In 14 patients receiving 
corticosteroids at baseline, daily prednisone doses decreased from 0.44 mg/kg/day (IQR, 0.31–1.09) to 0.11 mg/kg/day (IQR, 
0.02–0.24) (P < 0.01), and 5 of 10 patients with CANDLE achieved lasting clinical remission. The patients’ quality of life and 
height and bone mineral density Z-scores significantly improved, and their IFN biomarkers decreased. Three patients, two 
of whom had genetically undefined conditions, discontinued treatment because of lack of efficacy, and one CANDLE patient 
discontinued treatment because of BK viremia and azotemia. The most common adverse events were upper respiratory 
infections, gastroenteritis, and BK viruria and viremia.
CONCLUSION. Upon baricitinib treatment, clinical manifestations and inflammatory and IFN biomarkers improved in patients 
with the monogenic interferonopathies CANDLE, SAVI, and other interferonopathies. Monitoring safety and efficacy is 
important in benefit-risk assessment.
TRIAL REGISTRATION. ClinicalTrials.gov NCT01724580 and NCT02974595.
FUNDING. This research was supported by the Intramural Research Program of the NIH, NIAID, and NIAMS. Baricitinib was 
provided by Eli Lilly and Company, which is the sponsor of the expanded access program for this drug.
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Results
Clinical manifestations of CANDLE, SAVI, and other interferonop-
athies. Between October 2011 and October 2016, we treated 18 
patients, 10 with genetically confirmed CANDLE, 4 with genet-
ically confirmed SAVI, and 4 patients with other interferonopa-
thies. One patient was later found to have Aicardi Goutières syn-
drome 5 (AGS5), and one had a novel disease-causing mutation. 
The baseline demographics and clinical characteristics are sum-
marized in Table 1. All of the CANDLE and SAVI patients devel-
oped disease symptoms in the first 2.5 weeks of life. The mean 
age at enrollment was 12.5 years (range, 1.2–24.1); 72% of patients 
were below the third percentile for height; and 50% of patients 
were below the third percentile for weight (Table 1). Fourteen of 
eighteen (78%) patients were on chronic corticosteroid treatment 
for an average of 5.7 years (range, 1–17 years) prior to entry into the 
program. Three patients with SAVI and one patient with CANDLE 
had failed and discontinued corticosteroids prior to enrollment. 
All patients had failed in the use of 1 to 6 conventional and/or bio-
logic DMARDs. Most patients had frequent and prolonged hospi-
talizations prior to enrollment.
Clinical symptoms improve upon treatment with baricitinib. All 
patients underwent dose escalation until they reached optimal 
tolerated treatment doses (Figure 1A). The median duration in the 
program at the time of analysis was 1,023 days, or 2.8 years (IQR, 
842–1,419.5); patients had been on optimized doses for a median 
of 897 days, or 2.5 years (IQR, 639–1,160 days) (Supplemental 
Table 1; supplemental material available online with this article; 
https://doi.org/10.1172/JCI98814DS1). At the last NIH visit, 12 of 
18 (67%) patients fulfilled the diary score improvement criteria 
(80% of CANDLE, 75% of SAVI, and 1 of 4 [25%] patients with 
other interferonopathies). Of the 14 patients on corticosteroids at 
baseline, 10 of 14 (71%) fulfilled the corticosteroid improvement 
criteria (Table 2 and Supplemental Table 3). The median diary 
score decreased from 1.3 (IQR, 0.93–1.78) at baseline to 0.25 (IQR, 
0.10–0.63) (P < 0.0001). The median corticosteroid dose dropped 
from a prednisone equivalent dose of 0.44 (IQR, 0.31–1.09) 
mg/kg/day at baseline to 0.11 (IQR, 0.02–0.24) mg/kg/day 
(P < 0.005) (Table 3). All available data were used in a repeated- 
measures model to assess responses over time. Least-squares 
means for diary scores and corticosteroid dose decreased from 
baseline (phase 1), during the baricitinib dose escalation (phase 2), 
and further when optimal treatment doses were reached (phase 
3), and remained stable during the last 90 days of the observa-
tion period (phase 4). Patients were weaned from corticosteroids 
during dose escalation and were further weaned on optimal tol-
erated baricitinib doses (P < 0.001 for both, respectively, Figure 
1B). Patient pain, overall wellbeing, and quality of life improved 
with treatment (Figure 2): 5 (50%) patients with CANDLE 
achieved remission with no disease symptoms (disease-specific 
daily symptom score [DDS] <0.15) and normal C-reactive pro-
tein (CRP), despite discontinuation of corticosteroids (Table 2). 
The patients’ CRP was below 5 mg/l in 84.6% of the subsequent 
visits, and the IFN response gene scores were normal in 66.7% of 
visits at the last follow-up, which encompassed a mean of 654.4 
(range, 581–822) days after the patients first achieved remission 
criteria until data analysis, suggesting durable remission (Supple-
mental Table 4). The clinical responses were most pronounced in 
Introduction 
The IFN-mediated autoinflammatory diseases CANDLE (chronic 
atypical neutrophilic dermatosis with lipodystrophy and elevated 
temperatures) and SAVI (stimulator of IFN genes–associated 
[STING-associated] vasculopathy with onset in infancy) are Men-
delian innate immune–dysregulatory disorders that present early 
in life with fevers, sterile organ inflammation, and a high type I 
IFN response gene signature (IRS) in peripheral blood cells (1, 2) 
and are part of the spectrum of conditions termed interferonop-
athies (3). CANDLE is caused by loss-of-function mutations in 
genes encoding proteasome complexes that regulate protein deg-
radation (4–8). Patients with CANDLE present with fever, neu-
trophilic panniculitis, lipodystrophy, cytopenias, myositis, and 
lymphocytic aseptic meningitis. Forty to eighty percent of patients 
develop systemic hypertension, metabolic syndrome, and hepatic 
steatosis, often in the first decade of life (2). SAVI is caused by 
gain-of-function mutations in the viral sensor STING, resulting 
in constitutive transcription of the potent antiviral cytokine IFNβ 
(9–11). Patients present with cold-induced acral vasculitis result-
ing in loss of digits and interstitial lung disease, the latter of which 
may be the presenting symptom (2, 9).
Both syndromes respond poorly to biologic disease–modifying 
antirheumatic drugs (DMARDs) that target proinflammatory cyto-
kines (i.e., IL-1, TNF, and IL-6) (8, 9) or to conventional DMARDs. 
A high IRS is absent in patients with clinically active autoinflamma-
tory diseases who respond to treatment with IL-1–blocking agents 
(9, 12). Together, these findings support a potential role for type I 
IFN in propagating systemic organ inflammation and damage and 
high mortality rates (2).
Until recently, treatments that block IFN signaling have not 
been available. However, the JAK/STAT pathway constitutes the 
principal signaling pathway for cytokine and growth factor recep-
tors including the IFN-α/β receptor (IFNAR) and the IFN-γ recep-
tor (IFNGR) (13, 14). Small molecules that inhibit JAKs reduce 
type I and type II IFN–induced STAT1 phosphorylation (p-STAT1) 
in CANDLE and SAVI patients in vitro (7, 9), which suggested their 
potential utility in reducing the IFN signaling and disease man-
ifestations in these patients. In October 2011, we developed an 
expanded access program with baricitinib, a selective JAK1 and 
JAK2 inhibitor (15) that is currently approved for the treatment of 
moderately to severely active rheumatoid arthritis (RA) in adults 
(16) in over 40 countries including European countries, Japan, and 
and the United States, to treat patients with CANDLE, SAVI, and 
other presumed interferonopathies. Data were collected to ensure 
patient safety and assess benefit and to determine whether contin-
uation of baricitinib administration was justified.
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improvements and lowered their corticosteroid dose to less than 
0.15 mg/kg/day (Supplemental Figure 2, C–H).
Prior to baricitinib treatment, the patients’ growth and physi-
cal maturation were delayed, with the mean bone age being lower 
by 3.49 ± 3.99 years relative to their chronological age (Supple-
mental Figure 3). On baricitinib, 13 patients with growth potential 
improved their mean height Z-scores from –4.03 ± 2.64 to –3.19 ± 
2.33, with catch-up growth observed in 9 patients who were able 
to taper their corticosteroids to doses below 0.16 mg/kg/day (Fig-
ure 4, A and B, Supplemental Table 5, and Supplemental Figure 
4, A–E). Bone mineral density increased, with a mean Z-score 
change from –3.25 ± 1.97 to –2.20 ± 1.36 (P < 0.005) (Figure 4A 
and Supplemental Table 6).
At baseline, 6 of 10 patients with CANDLE had metabolic 
syndrome; 10 patients (7 with CANDLE and 3 other patients) had 
hyperlipidemia; 7 pediatric patients on corticosteroids (C3, C5, C6, 
C7, S1, O1, and O4) met the Centers for Disease Control and Pre-
vention (CDC) BMI criteria for obesity; and 2 patients had hepatic 
steatosis (1 patient with CANDLE [C5] and 1 with SAVI [S2]). On 
patients with CANDLE, while in patients with SAVI, the vasculitis 
flares improved but still occurred, albeit with reduced duration 
and severity; none of the SAVI patients experienced further loss 
of digits (Figure 3, A–H and Supplemental Figure 2, A and B). The 
patient with SAVI on corticosteroid treatment at baseline had an 
initial reduction but increased corticosteroid doses prior to the 
final visit because of subjective symptoms of respiratory difficul-
ties. In the context of stable pulmonary function tests (PFTs) and 
chest CT, her corticosteroid dose was subsequently reduced to 
0.11 mg/kg/day.
Three patients discontinued treatment. Two patients without 
a genetic diagnosis stopped after 244 and 98 days of treatment, 
respectively one because lack of efficacy and the other because 
of osteonecrosis and an unsatisfactory treatment response. One 
CANDLE patient, for whom the corticosteroid dose could not be 
tapered, developed BK viremia and azotemia and discontinued 
treatment (Supplemental Figure 1). The 2 patients with other inter-
feronopathies, both of whom stayed on treatment (1 patient with 
AGS5 and 1 with a novel disease-causing mutation), had symptom 
Table 1. Baseline demographics and clinical characteristics (n = 18) 
Value Value
Demographic characteristics Clinical characteristics
Age at enrollment in yr,  mean (min–max) 12.5 (1.2–24.1) Clinical manifestations, no. (%)
Age group, no. (%)       Systemic inflammationG 18 (100)
      0–2 yr 1 (5)       Anemia 12 (67)
      3–6 yr 2 (11)       Basal ganglia calcifications (n = 16) 10 (62)
      7–10 yr 4 (22)       Height <3rd  percentile 13 (72)
      11–18 yr 5 (28)       Weight <3rd percentile 9 (50)
      ≥18 yr 6 (33)                                                                      Bone age, mean (min-max)H 
Sex, no. (%)                                                                        Delayed bone age (n = 13), yr 3.5 (0.4–12.3)
      Male 12 (67) CANDLE-specific (n = 10), no. (%)
Race or ethnic group, no. (%)       Panniculitis-induced lipodystrophy 10 (100)
      White 16 (89)       Joint contractures 10 (100)
      Black 2 (11)                                                                               MyositisI 8 (80)
      Hispanic 4 (22)       Metabolic syndrome J 6 (60)
Clinical characteristics (all patients)       Pulmonary arterial hypertension 1 (10)
By genetic diagnosis, no. (%) SAVI-specific (n = 4), no. (%)
      CANDLEA 10 (55)       Interstitial lung disease 4 (100)
      SAVIB 4 (22)       Cutaneous vasculitis 4 (100)
      Other interferonopathyC 4 (22)       Skin ulcers 3 (75)
Immunomodulators prior to baselineD, no. (%) 17 (94)       Amputation distal extremities 3 (75)
      ≥2 Immunomodulators prior to baseline 10 (55) Other interferonopathy (n = 4), no. (%)
      Mean use of immunomodulators prior to baseline 2.7 (0–6)       Panniculitis 4 (100)
Biologics prior to baselineE, no. (%) 13 (72)        Lipodystrophy 3 (75)
      ≥2 biologics prior to baseline 10 (55)       Arterial Hypertension 3 (75)
      Mean use of biologics prior to baseline 2.3 (0–6)       Livedo reticularis 2 (50)
Oral corticosteroidsF, no. (%) 14 (78)       CNS disease/stroke 1 (25)
      Mean exposure to oral corticosteroids, yr 5.7 (1–17)       IgA nephropathy/noncirrhotic portal hypertension 1 (25)
APSMB8 (5 homozygous, 1 compound heterozygous), PSMB4 (1 compound heterozygous), PSMB4/PSMB9 (2 digenic), and PSMA3/PSMB8 (1 digenic). 
BAll with de novo gain-of-function mutation N154S in TMEM173. CSAMHD1 (1 homozygous deletion), SAMD9L (1 patient), unknown (2 patients, 1 with a 
heterozygous PSMB8 mutation). DAzathioprine, colchicine, cyclosporine, cyclosphosphamide, dapsone, hydroxychloroquine, intravenous immunoglobulin 
(IVIG), leflunomide, methotrexate, mycophenolate mofetil, tacrolimus, thalidomide. EAdalimumab, abatacept, anakinra, canakinumab, etanercept, 
infliximab, rituximab, tocilizumab. FPrednisone or equivalent. GhsCRP >3.0 mg/l, ESR >25 mm/h. HBone age by Greulich and Pyle for 13 patients with open 
growth plates. IDocumented by MRI bilateral thighs. JAll patients with metabolic syndrome had arterial hypertension according to Ford criteria  (ref. 39). 
min, minimum; max, maximum. 
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improvement in the 2 patients with hepatic steatosis at baseline. 
In patients with CANDLE, myositis and aldolase levels improved 
on baricitinib treatment (P = 0.06) (Supplemental Table 9). In the 
3 SAVI patients with baseline lung disease, signs of chronic inter-
stitial lung disease, forced vital capacity (FVC), carbon monoxide– 
diffusing capacity (DLCO), and walking distance improved on 
baricitinib (Supplemental Table 10).
Hematologic and immunologic markers improve on treatment 
with baricitinib. At baseline, 12 of 18 (67%) patients were anemic, 
7 (39%) had lymphopenia, and 4 (22%) had thrombocytope-
nia. The hemoglobin concentration, absolute lymphocyte count 
(ALC), and platelet count increased during treatment in patients 
with cytopenias at baseline (P ≤ 0.05 for hemoglobin and ALC). 
In patients with normal cell counts at baseline, hemoglobin and 
ALCs trended nonsignificantly downward (Figure 4C).
At baseline, 60% of patients with CANDLE and all patients 
with SAVI had detectable autoantibodies against endothelial anti-
gens and targets including phospholipids (lupus anticoagulant 
and anti-cardiolipin Abs), antimyeloperoxidase and proteinase-3, 
and/or against nuclear antigens (ANA, SSA) and DNA (dsDNA). 
Autoantibody positivity significantly decreased during treatment 
(P = 0.013) (Supplemental Table 11), while cell subsets and Ig levels 
remained stable (Supplemental Figures 6 and 7).
Baricitinib suppresses inflammatory markers including the IFN 
signature and the serum IFN cytokine IP-10. Among the acute-
phase reactants (erythrocyte sedimentation rate [ESR] and CRP), 
CRP levels continuously decreased with treatment, and the 
reduction was largest in patients with CANDLE (Table 3, Figure 
baricitinib, BMIs improved to more normal values; in 4 of 5 under-
weight patients (C9, C10, S4, and O3), BMI improved in 2 patients 
(S4 and O3) and normalized in 2 other patients (C9 and C10). For 
5 of 7 obese patients, the BMI dropped to the overweight category 
(C3, C5, C6, S1, and O4), and 1 patient who was overweight at 
baseline became obese (S2) (Supplemental Table 7). The median 
lipid levels (HDL, LDL, and triglycerides) increased on barici-
tinib treatment (Supplemental Table 8). Three patients with CAN-
DLE (C3, C4, and C8) who had hyperlipidemia at baseline devel-
oped hepatic steatosis (Supplemental Figure 5, A–C), with no 
Table 2. Primary benefit assessment
Patient ID Primary benefitA 
(DDS) response
Secondary benefitB 
(corticosteroids) 
response
RemissionC
CANDLE (n = 10) 8/10 (80%) 8/9 (89%) 5/10 (50%)
SAVI (n = 4) 3/4 (75%) 0/1 (0%) 0/4 (0%)
OtherD (n = 4) 1/4 (25%) 2/4 (50%) 0/4 (0%)
All (n = 18) 12/18 (67%) 10/14 (71%) 5/18 (28%)
ADiary score reduction criteria include a mean daily diary score <0.5 for 
CANDLE and other interferonopathies or <1 for SAVI. BPrednisone reduction 
criterion is at least a 50% decrease from baseline or <0.15 mg/kg/day. 
CRemission criteria include a mean diary score <0.15, no prednisone, and a 
CRP <5 mg/l. DTwo patients (pts.), O1 and O3, discontinued treatment after 
244 and 98 days on the program, respectively.
Figure 1. Expanded access program overview and effect of baricitinib treatment on clinical outcomes. (A) Expanded access program overview. Phase 1: 
Time before the first baricitinib dose. Phase 2: Period of dose escalation, including the time between the first baricitinib dose and achievement of an opti-
mal dose regimen. Phase 3: Time on optimal baricitinib doses, excluding the last 90 days prior to the final visit. Phase 4: Ninety days prior to the final visit, 
with analysis of primary data (daily diaries, steroid doses, and biomarkers of IFN signaling). The program is ongoing. #The number of days in each phase is 
reported as the mean ± SD. For phases 2 and 3, patients O1 and O3 were not included in the calculation. Both patients discontinued treatment because of 
a lack of efficacy and/or osteonecrosis after only 77 and 56 days on optimal doses, respectively. (B) Effect of baricitinib treatment on clinical outcomes. To 
confirm trends in longitudinally collected data, the diary scores and corticosteroid doses were fitted to a repeated-measures model with “phase” as a cat-
egorical independent variable. Least-squares means with 95% CIs for each phase were assessed. *P < 0.05 and **P < 0.001 (both unadjusted) by 2-sided 
paired Student’s t test.
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The IFN score normalized in the 5 patients with CANDLE who 
achieved remission (Figure 5B). The IFN response gene score  and 
serum IP-10 levels significantly correlated with each other (Sup-
plemental Figure 9A). Both correlated significantly with daily 
symptoms (r = 0.26 and r = 0.37, P < 0.0001) and with lower doses 
of corticosteroids, indicating the ability to taper corticosteroid 
5A, and Supplemental Figure 8C). The ESR did not significantly 
decrease and remained elevated in most patients (Supplemental 
Figures 8, A and B).
Biomarkers of IFN signaling, serum levels of the chemokine 
IP-10, and the IFN response gene score significantly decreased 
during treatment with baricitinib (Table 3 and Figure 5, B–D). 
Table 3.  Change of measure of disease activity and improvement from baselineA
Measure  Open-label treatment P value
Before baricitinibB After baricitinib
Primary measures of clinical response (n = 18)
Global diary scoreC <0.0001
      Median 1.30 0.25
      IQR 0.93–1.78 0.10–0.63
Dose of prednisone or prednisone equivalent dose 
(mg/kg/d)D 
<0.005
      Median 0.44 0.11
      IQR 0.31–1.09 0.02–0.24
Other measures of clinical response (n = 16)
CHAQ scoreE <0.05   
      Median 1.69 1.13
      IQR 0.53–2.09 0.03–1.75
VAS for pain (mm)F <0.01
      Median 38.50 4
      IQR 11.75–75.75 0.25–27.50
Parent’s/patient’s global assessment (mm)F NS
      Median 48 26
      IQR 18–55 1–36
Physician’s global assessment  (mm)F <0.001
      Median 90 2.50
      IQR 55.50–96.25 0.75–5.50 
Height (cm)G 110.0 ± 26.16 126.52 ± 26.22 <0.001
Weight (kg) 33.78 ± 20.15 43.24 ± 21.59 <0.001
Measures of laboratory responses (n = 18)
CRP (mg/l)  NS
      Median 15.9 2.9
      IQR 4.25 –51.8 1.2–16.4
Erythrocyte sedimentation rate (mm/h) NS
      Median 53 37
      IQR 16.25–71.75 10.5–74
IFN biomarker responses (n = 18) 
25-gene IFN score <0.01
      Median 417.5 113.3
      IQR 216.8–735.1 18.5–288.8
Serum IP-10 levels  <0.005
      Median 9196.7 1857.6
      IQR 2814.7–13299.4 868.7–4587.2
ACutoff for data analysis was October 31, 2016. BAll subjects except 3 (C1, C9, and S2) completed the Childhood Health Assessment Questionnaire (CHAQ), 
VAS for pain, and parent’s/patient’s global assessment at baseline or within 10 months before the first dose of baricitinib. Subject C1 completed the 
questionnaires 32 months prior to enrollment, and subjects C9 and S2 completed the questionnaires 9 months and 2 months after the first dose of 
baricitinib, respectively. CMedian daily scores of 5 symptoms for CANDLE and CANDLE-like patients (fever, rash, musculoskeletal pain, headache, and 
fatigue) were evaluated daily with the use of a scale that ranged from 0 (no symptoms) to 4 (severe symptoms). The maximal daily score measured was 4; 
the minimal score was 0. Median daily scores for 6 symptoms in SAVI patients (fever, rash, musculoskeletal pain, fatigue, respiratory symptoms, ulcers/
ischemic lesions) were evaluated daily using a scale that ranged from 0 (no symptoms) to 4 (severe symptoms). The maximal daily score measured was 4; 
the minimal score was 0. DValues are for 14 patients who were receiving corticosteroids when they entered the study. ECHAQ is a standardized test for the 
assessment of disability (range, 0–3), with higher scores indicating more severe impairment. Data for the subjects discontinued from the study (O1 and O3) 
are not included. FA VAS was used, in which a value of 100 mm indicates the worst possible measure for the condition assessed by the test. Data for the 
subjects discontinued from the study (O1 and O3) are not included. GValues are for 13 patients with open growth plates only.
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doses (r = 0.24 and r = 0.44, P < 0.005 and P < 0.0001, respective-
ly) (Supplemental Table 12 and Supplemental Figures 9, B and C). 
The IFN biomarkers, IP-10 levels, and IFN response gene score 
correlated better with the ability to taper corticosteroid doses than 
with the acute-phase reactants (ESR and CRP). Prior to treatment, 
the diurnal variability of IFN scores obtained in 1 day was high. 
The fluctuation correlated with higher morning scores, and the 
daily variability was greatly reduced during baricitinib treatment 
when overall IFN scores decreased (Supplemental Figure 10A).
We measured IFN-α–stimulated STAT1 phosphorylation 
to assess type I IFN receptor responsiveness during baricitinib 
treatment; the IFN-α stimulation–induced STAT1 phosphoryla-
tion was reduced to the lower tertile measured in healthy con-
trols (Supplemental Figure 10B). While patients with CANDLE 
were hyper responsive to IFN-α stimulation before treatment 
with baricitinib (7), most patients with SAVI had maximal STAT1 
phosphorylation and did not respond to IFN-α stimulation (9). 
On baricitinib, the IFN response in patients with SAVI recovered 
to the levels detected in patients with CANDLE. Other cyto-
kines that significantly decreased in baricitinib-treated patients 
included MCP-1, granulocyte-macropage CSF (GM-CSF), IL-15, 
and IL-5 (Supplemental Figure 11).
Safety summary. Overall, baricitinib was well tolerated. At the 
time of safety analysis (June 2017), the mean baricitinib exposure 
was 3.5 years (range, 2.3–5.6 years for ongoing patients), repre-
senting 63 patient years of exposure. No deaths were reported 
during the program. Two patients (11%) with inadequate responses 
discontinued treatment because of adverse events. One patient 
(O3) with an undifferentiated interferonopathy had evidence of 
osteonecrosis (right femur) 3 days after starting baricitinib and was 
taken off the drug because of progression after 14 weeks of baric-
itinib treatment. Eighteen months after discontinuing baricitinib, 
the patient died as a result of a worsening of preexisting nodular 
regenerative hyperplasia and portal hypertension complicated by 
recurrent esophageal variceal hemorrhages, IgA nephropathy, and 
renal insufficiency. One patient with CANDLE (C7) developed azo-
temia in the context of BK viruria and viremia and discontinued treat-
ment after 117 weeks because of acute kidney injury. This patient died 
Table 4. Treatment-emergent adverse events (infections)A
Adverse event CANDLE syndrome, n = 10 CANDLE-related conditions, 
n = 4
SAVI,  
n = 4
Total, 
 n = 18
 n (%) n (%) n (%) n (%)
Patients with infections 10 (100.0) 2 (50.0) 4 (100.0) 16 (88.9)
Respiratory tract infections 10 (100.0) 2 (50.0) 3 (75.0) 15 (83.3)
   Upper respiratory tract infection –  
   no identified organism
10 (100.0) 2 (50.0) 2 (50.0) 14 (77.8)
   PneumoniaB 4 (40.0) 0 2 (50.0) 6 (33.3)
   Upper respiratory tract infection –  
   with identified organismC
4 (40.0) 1 (25.0) 0 5 (27.8)
   Sinusitis 3 (30.0) 1 (25.0) 1 (25.0) 5 (27.8)
   Otitis media 4 (40.0) 1 (25.0) 0 5 (27.8)
   Pharyngitis 2 (20.0) 1 (25.0) 0 3 (16.7)
BK viremia 6 (60.0) 1 (25.0) 2 (50.0) 9 (50.0)
Gastrointestinal infectionsD 6 (60.0) 2 (50.0) 1 (25.0) 9 (50.0)
Urinary tract and genital infectionsE 4 (40.0) 1 (25.0) 1 (25.0) 6 (33.3)
Skin, nail, and oral infections 6 (60.0) 2 (50.0) 4 (100.0) 12 (66.7)
   Bacterial infectionsF 3 (30.0) 2 (50.0) 3 (75.0) 8 (44.4)
   Other infectionsG 2 (20.0) 0 3 (75.0) 5 (27.8)
   Fungal infectionsH 3 (30.0) 1 (25.0) 0 4 (22.2)
   Viral infectionsI 2 (20.0) 0 1 (25.0) 3 (16.7)
   Herpes zoster 2 (20.0) 0 0 2 (11.1)
Eye infections J 3 (30.0) 0 0 3 (16.7)
Device-related infectionsK 3 (30.0) 0 0 3 (16.7)
Bacteremia and osteomyelitisL 0 0 2 (50.0) 2 (11.1)
ATreatment-emergent infections are defined as events that were new or that worsened after starting baricitinib treatment. Patients with multiple 
occurrences of a specific event are counted once for the event. Patients with multiple events within a grouped term are counted once for the group term. 
BPneumonia includes: pneumonia, bacterial pneumonia, Pneumocystis jirovecii pneumonia, and Hemophilus bacteremia in the context of Pneumocystis 
jirovecii pneumonia. CUpper respiratory tract infection with an identified organism includes: influenza, corona virus infection, parainfluenza virus infection, 
respiratory syncytial virus infection, and rhinovirus infection. DGastroenteritis includes: gastroenteritis, viral gastroenteritis, gastrointestinal viral infection, 
Clostridium difficile infection, and rotavirus infection. E Urinary Tract and Genital Infections include: urinary tract infection, urosepsis and pyelonephritis, 
epididymitis, and vulvovaginitis. FBacterial infections include: paronychia, staphylococcal infection, cellulitis, and folliculitis. GOther infections include: wound 
infection, tooth abscess, tooth infection, skin infection, and pustular rash. HFungal infections include: oral candidiasis, skin candida, fungal skin infection, 
and tinea pedis. IViral infections include: molluscum contagiosum, herpes simplex, and viral rash. JEye infections include: conjunctivitis, hordeolum, and viral 
conjunctivitis. KDevice-related infections include: device-related and stoma site infections. LBacteremia and osteomyelitis include: localized infection and 
osteomyelitis. n, number of patients.
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4 months later as a result of exacerbation of CANDLE syndrome, 
in the context of a respiratory tract infection and interstitial lung 
disease. Fifteen patients (83%) had at least 1 serious adverse event 
(SAE) (Supplemental Table 13). In most instances, the SAEs resolved 
without interruption of baricitinib treatment. Treatment-emergent 
infections were observed in 16 patients (89%) (Table 4). Upper respi-
ratory tract infections were most frequent. Two patients developed 
herpes zoster, with unilateral lesions restricted to 2 to 3 contiguous 
dermatomes. Transient cytopenias developed in the context of 
infections and intermittent disease exacerbations (Supplemental 
Tables 14 and 15). An unexpected finding was the development of 
polyomavirus (BK) viremia in patient C7. While 2 patients had low- 
titer intermittent BK viremia before baricitinib treatment, 8 addi-
tional patients developed intermittent BK viremia during barici-
tinib treatment. In contrast to the first patient who had high-titer 
BK viremia in the context of worsening renal disease, the copy 
number in the other patients was low and variable, with stable low- 
copy-number viremia and stable renal function over time (Supple-
mental Table 16).
Discussion
We found that treatment with baricitinib improved disease signs 
and symptoms and allowed a significant reduction of cortico-
steroid treatment in patients with CANDLE and SAVI and in 2 
patients with other interferonopathies in an expanded access 
program. Of the 10 patients with CANDLE, 5 (50%) patients 
were able to permanently discontinue corticosteroid therapy, 
without a return of disease symptoms; their inflammatory mark-
ers normalized, and they achieved durable inflammatory remis-
sion on baricitinib. In patients with SAVI, baricitinib treatment 
improved the vasculitis flares and prevented the progression of 
spontaneous amputations and the development of gangrene. 
Baricitinib also stabilized interstitial lung disease by preserv-
ing pulmonary function indices including DLCO and improved 
walking distances. Despite these clinical improvements, inflam-
matory markers did not normalize in any of the patients with 
SAVI, and although IFN scores decreased, the absolute levels 
remained elevated. These findings are consistent with 2 previous 
reports on a total of 7 patients with SAVI who were treated for 3 to 
15 months with the JAK inhibitor ruxolitinib (17, 18).
Among the 4 patients with other (initially uncharacterized) 
interferonopathies, 2 patients, for whom a genetic diagnosis could 
not be established did not respond and discontinued treatment. 
The 2 responders had both severe panniculitis and lipoatrophy. One 
of the patients had peripheral vasculitis, and at the age of seven 
years developed moyamoya-like cerebral vasculopathy resulting in 
vascular occlusion and stroke. She was later found to be homozygous 
for a SAMHD1 deletion, which allowed a retrospective diagnosis of 
later-onset AGS5 (19). The second patient had nodular panniculitis, 
lipoatrophy, and marked systemic inflammation. This patient was 
later found to have a novel frameshift mutation in SAMD9L, suggest-
ing a possible novel interferonopathy. The 2 responders had higher 
25-gene IFN scores at baseline compared with those of the 2 non-
responders, thus suggesting that a combination of clinical pheno-
type and grossly elevated IFN scores might be useful in predicting 
responses to IFN-blocking treatments such as JAK1/2 inhibition.
Most patients with CANDLE and SAVI and some other interfer-
onopathies have significant growth and bone maturation delays and 
low bone mineral density. The significant improvement in height 
and bone mineral density Z-scores demonstrates that the baricitinib 
dosing regimen we developed to optimize disease control allows for 
catch-up growth and bone production, which was most prominent 
in patients who were able to reduce corticosteroid doses to less 
than 0.16 mg/kg/day. These observations ease concerns that JAK 
inhibitors could reduce growth hormone (GH) function through 
inhibition of GH receptor–induced tyrosine kinase JAK2 phosphor-
ylation (20, 21). Despite improvement in inflammatory markers, 
hyperlipidemia and hepatic steatosis did not improve in the patients 
with CANDLE. In fact, 3 patients with CANDLE on baricitinib treat-
ment developed hepatic steatosis, which manifested as a moderate 
decrease in their BMIs from baseline, pointing to a role of protea-
some dysfunction in the development of hepatic steatosis that is 
independent of IFN-mediated inflammation (22).
The abnormal IFN responses in vivo were modulated by reduc-
ing IFN-α–induced STAT1 phosphorylation and downstream IFN 
targets such as serum IP-10 levels and an IFN response gene score 
Figure 2. Self-reported and physician’s global assessments by disease subgroup. Parent’s or patient’s overall assessment of pain and health (Pt. global) and 
the physician’s assessment (MD global) were measured using a visual analog scale (VAS), in which a value of 100 mm indicates the worst possible measure for 
the condition assessed by the test. Quality of life (PedsQL) was measured using a standardized age-matched test that ranged from 0% to 100%, with higher 
percentages indicating improvement. Data are presented by disease, with CANDLE in red, SAVI in blue, and other interferonopathies in green. Only the 2 
patients who stayed in the study are shown. Darker shades indicate pretreatment, and lighter shades indicate the last included visit on baricitinib treatment. 
**P < 0.05 and ***P < 0.001 (both unadjusted) by 2-sided paired Student’s t test.
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after treatment with baricitinib. The reduction in IFN biomarkers 
correlated with the improvement of clinical signs and symptoms 
and with the ability to taper the corticosteroid dose. Peripheral 
blood mononuclear cells (PBMCs) from most untreated patients 
with SAVI showed high constitutive STAT1 phosphorylation and 
were unresponsive to further IFN-α stimulation (9). However, we 
observed decreased constitutive activation and restored type I 
IFN receptor responsiveness with baricitinib treatment. We also 
observed reductions in serum levels of GM-CSF and its downstream 
mediator, the chemokine MCP-1 (CCL2), with baricitinib treatment 
(23). GM-CSF promotes myeloid differentiation toward inflam-
matory, M1-like macrophages, and CCL2 promotes monocyte/ 
macrophage recruitment to sites of tissue injury or infection (24–
26). GM-CSF, particularly in the context of IFNs, primes monocytes 
to amplified stimulation-induced cytokine and chemokine over-
production that includes the production of IFN biomarkers (27) 
through epigenetic remodeling (28). The reduction in diurnal vari-
ability of the IFN response gene score and the modulation of IFN-α–
induced STAT1 phosphorylation in baricitinib-treated patients may 
be consistent with a reset of the IFN receptor sensitivity through 
epigenetic remodeling mediated by JAK inhibition, a mechanism 
that was recently suggested in a murine model treated with IFN-α 
and a JAK inhibitor (29). The impact of JAK inhibition on epigen-
etic remodeling as a molecular mechanism that may attenuate an 
IFN-dependent amplification loop (1) needs further evaluation.
Overall, the mean drug exposure levels to optimize disease 
control in the context of an acceptable safety profile in our patients 
were 1.83-fold higher than for patients with rheumatoid arthritis 
taking 4 mg/day baricitinib (30); the severe disease manifesta-
tions and the need to target type I IFN signaling are likely reasons 
for the higher exposures in our patients.
Treatment with baricitinib was overall well tolerated. Consis-
tent with studies of adult patients with rheumatoid arthritis, upper 
respiratory tract infections were the most frequently reported 
treatment-emergent adverse events, and 2 patients developed her-
pes zoster (30, 31). However, the observation of viral reactivation 
with BK virus (BK viremia and viruria) was unique in this patient 
population. Patients’ viral titers in the urine and blood remained 
stable over a 2-year period on treatment. While the clinical signifi-
cance of measurable BK titers remains uncertain (32–34), viral titers 
in the blood should be monitored in this vulnerable population.
Although the number of patients enrolled was small, the long 
duration of treatment (2.3–5.6 years and continuing), the durable 
responses to treatment, and the reduction in inflammatory mark-
ers confirm the long-lasting effect of baricitinib treatment.
In summary, our data show that clinical signs and symptoms 
of patients with CANDLE and SAVI improved with baricitinib 
treatment. The decrease in systemic and organ-specific inflamma-
tion in terms of IFN biomarker reduction indicates a causative role 
for chronic IFN signaling in disease pathogenesis in patients with 
type I IFN–mediated diseases (1, 35).
Methods
Patients
Patients with genetically confirmed CANDLE or SAVI or a suspected 
undifferentiated interferonopathy, who were referred to our center for 
Figure 3. Improvement in clinical disease manifestations in CANDLE and 
SAVI  patients treated with baricitinib. (A–D) Images of 2 patients with 
CANDLE who achieved the remission criteria (C2 and C10, respectively) are 
shown. Pretreatment images of the face show typical distribution of facial 
panniculitis with periorbital swelling and erythema as well as lipodystro-
phy affecting temporal regions and areas above and below the zygomatic 
bone. Lip swelling is also evident. Post-treatment images show complete 
resolution of areas of panniculitis on the face and neck. (E and F) Images of 
2 of the 4 patients with SAVI are shown. Images of the lower leg of a SAVI 
patient (S3) show extensive eschar formation overlying infected, nonheal-
ing ulcers on the left lower leg. After treatment, the ulcers healed, with 
complete reepithelialization. (G and H) Images of the right palmar surface of 
the hand of a patient with SAVI (S4) show chronic cutaneous vasculitis that 
resulted in partial amputation of the second and third fingers and complete 
loss of the fourth and fifth fingers. On baricitinib treatment, a significant 
improvement in cutaneous vasculitis resulted in preservation of the fingers 
without further tissue loss.
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are without other satisfactory treatment options. Data presented here 
are from patients enrolled at the NIH. Data were collected in a com-
pany-provided database and in a clinical database at the NIH.
Treatment with the JAK inhibitor baricitinib and dosing adjust-
ments and escalation. At the start of the program, pediatric pharma-
cokinetic (PK) data were not available, and baricitinib was started 
orally at 100 μg once a day. As PK and clinical response data became 
available, the dose escalation scheme for baricitinib was modified 
(36). An inadequate response, defined as elevated average diary 
scores and active clinical disease (diary scores ≥0.5 for CANDLE 
evaluation and treatment recommendations and who were 17.5 months 
of age or older, weighed 8.5 kg or more, and had active clinical disease 
(CANDLE diary score ≥0.5 or a SAVI diary score ≥1.0) were eligible to 
participate in this study. Patients had to receive or to have previously 
failed treatment with oral corticosteroids (≥0.15 mg/kg/day prednisone 
or its equivalent).
Program design and treatment
The open-label expanded access program (ClinicalTrials.gov 
NCT01724580) provides access to baricitinib to eligible patients who 
Figure 4. Improvement in longitudinal growth and hematologic parameters. (A) Clinically significant improvement was seen in height Z-scores and the 
percentiles of patients with growth potential (n = 13) when comparing data from before baricitinib treatment with data from the last visit. Mean height 
Z-scores improved from –4.03 ± 2.64 to –3.19 ± 2.33, with catch-up growth observed in 9 patients whose improvement translated into a mean height 
percentile increase from the 1.4th percentile to the 7.2nd percentile. (B) Photos of a patient with CANDLE (C8) with stunted growth since 2 years of age and 
a severe delay in bone age (chronological age of 14.3 years vs. bone age of 2 years). Within 30 months of treatment, her linear height increased from 90 cm 
to 106.8 cm, and her bone age improved from 2 years to 7.8 years. (C) Signs of bone marrow immunosuppression improved in all patients but 2 (C1 and O3), 
with increases in platelet counts, ALCs, and hemoglobin (Hgb) levels. Patient C1 continues to have persistent lymphopenia (ALC of 0.5), and patient O3 
(discontinued from the program because of a poor response to treatment and osteonecrosis) had lower hemoglobin and platelet counts at the time of his 
last visit. This patient had multiple comorbidities including upper gastrointestinal bleeding, esophageal varices, IgA nephropathy, and idiopathic throm-
bocytopenia. **P < 0.05 (unadjusted) by paired Student’s t tests were used for both calculations; a 1-sided t test was used for height (in A) and paired 
Student’s t tests were used for all calculations, including the two asterisks  (in C).
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DDS score. Primary benefit was defined as a decrease in the DDS 
score to less than 0.5 for patients with CANDLE and other interfer-
onopathies and to less than 1.0 for patients with SAVI. The cutoffs 
corresponded with clinically meaningful responses to treatment. Each 
patient or caregiver was instructed to complete the diary at approxi-
mately the same time every day and to rate the impact of each symp-
tom on the patient. The average score for each symptom was calculated 
and summed and divided by the number of assessed symptoms (see 
Supplemental Methods). Diary scores were used in the assessment of 
disease activity, the need for baricitinib dose increases, and the initia-
tion of steroid dose tapering. Diary scores were collected for 2 weeks 
prior to baricitinib administration and every day throughout the pro-
gram. Patient O3 completed diaries for 76.7% of the days, and all of the 
other patients completed diaries for more than 92% of the days (Supple-
mental Table 2).
Reduction in daily corticosteroids. Secondary benefit was assessed 
for patients on treatment with corticosteroids at enrollment. Success-
ful reduction was defined as a reduction in the corticosteroid dose to 
less than 0.15 mg/kg/day of the prednisone equivalent or a decrease 
of at least 50% of the patient’s daily dose at baseline.
Other clinical outcome measures. We measured clinical remis-
sion, change in disability, quality of life, and patient and physician 
global assessments. Z-scores for height, weight, BMI, bone age, and 
or ≥1 for SAVI, or ongoing clinical symptoms of disease activity), 
in the absence of signs of drug toxicity (i.e., drop in hemoglobin), 
allowed increases in the daily dose of baricitinib. Dose escalations 
were initially allowed when the PK baricitinib peak and trough lev-
els were within the range of those observed in healthy adult con-
trol subjects or in patients with RA or psoriasis (Eli Lilly internal 
data); further dose increases were approved in amendments and 
monitored according to the PK data. We determined the visit at 
which the enrolled patients reached optimal tolerated dosing for 
baricitinib (Supplemental Table 1). Population pharmacokinetic 
(PopPK) analyses were performed at optimized tolerated baricitinib 
doses (36). The mean exposures, measured as AUC24,SS, were 1.83-fold 
higher than those obtained in adult RA patients receiving oral barici-
tinib doses at 4 mg once daily in phase III studies. A dosing table has 
been published previously (36).
Clinical benefit assessment
We collected limited efficacy data on the expanded access protocol 
(diary scores, corticosteroid doses, medications, safety data) to aid in 
the determination of dose titration and ensure evidence of the benefit 
justifying the risk. Additional efficacy data were collected according to 
the natural history protocol or as part of routine patient care (see Sup-
plemental Methods).
Figure 5. Assessment of conventional inflammatory parameters (CRP) and IFN biomarkers (serum IP-10 levels and 25-gene IFN score) with baric-
itinib treatment. (A) CRP levels dropped most significantly in CANDLE patients, with CRP levels returning to normal in 5 of 10 of these patients. 
The patients with other interferonopathies (O2 and O4) who stayed in the program had improved CRP levels. The 2 patients who discontinued 
the program because of a lack of efficacy had no improvement and are circled. **P < 0.05 (unadjusted by paired 2-sided Student’s t-test). Data 
represent the mean ± SD. (B) The 25-gene IFN score was graphed for the baseline score and the IFN score obtained at the last included visit only. 
Colors indicate data by disease, with CANDLE in red, SAVI in blue, and other interferonopathies in green. Statistical data obtained by paired 2-sided 
Student’s t-test. The IFN score normalized in 5 of 10  patients with CANDLE who achieved the remission criteria. (C and D) Longitudinally assessed 
serum IP-10 levels and 25-gene IFN score measurements were fitted to a repeated-measures model with “treatment phase” as a categorical 
independent variable. Least-squares means (LSM) of serum IP-10 and IFN response gene score with 95% CIs for each phase are graphed. *P < 0.05 
(unadjusted) by paired 2-sided Student’s t-test.
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the study evaluation; and phase 4 included the last 90 days before the 
last included visit (all patients were on optimal tolerated doses) (Sup-
plemental Table 1). To confirm trends in longitudinally collected data 
(diary scores, prednisone dose, acute phase reactants and IFN biomark-
ers), the data were fitted to a repeated-measures model with “phase” as 
a categorical independent variable. The least-squares means with 95% 
CIs for each phase were assessed. The Cochran-Mantel-Haenszel test 
was used to analyze the association between binary outcomes.
Assessment of associations between clinical outcomes, IFN biomark-
ers, and conventional biomarkers (ESR and CRP). A linear mixed mod-
el with a random slope and intercept and an unstructured variance- 
covariance matrix was used to assess the association of clinical out-
come measures (DDS and corticosteroid dose) with biomarkers of IFN 
signaling (serum IP-10 levels and the 25-gene IFN score. To determine 
the correlation between repeated measures, we applied a method 
based on a reconfiguration of the X and Y variables by using the SAS 
PROC MIXED statement (38).
Study approval
The program was approved by the IRBs of the NIH, NIAMS, NIDDK, 
and NIAID. All patients were coenrolled in the NIH Natural History 
Protocol of Autoinflammatory Diseases (NCT02974595), under which 
clinical and biomarker data were assessed. Patients or their parents 
provided written informed consent. Additional written photo consent 
was obtained from patients included in this manuscript. Patients were 
evaluated at baseline, monthly for the first 12 months, and every 3 
months thereafter. The program is currently ongoing.
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enrollees would be small, and therefore no formal statistical analyses 
were planned. Null and alternative hypotheses were not defined pro-
spectively, and analyses were not adjusted for multiple comparisons. 
We assessed the mean change in clinical measures obtained under the 
expanded access program, including diary scores, prednisone doses, 
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Assessment of dose-response relationships of clinical and biomarker 
measures. As the dose of baricitinib was titrated to the clinical response, 
we determined the visit at which the patients were started on the opti-
mal tolerated baricitinib doses (Supplemental Table 1). For each patient, 
the timeline was divided into 4 study phases, and the primary outcome 
was averaged over each period, resulting in 4 averages per period per 
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start date and the first day of treatment; phase 2 (post-treatment pre-
optimal baricitinib dose period) included the dose escalation period, 
which started with the second day of treatment and continued up to 
the first day that an optimal tolerated dose was achieved; phase 3 (post- 
optimal tolerated dose period) started with the day the optimal toler-
ated dose was achieved and continued until 90 days before the end of 
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